申请人:Sunshine Lake Pharma Co., Ltd.
公开号:US10183917B2
公开(公告)日:2019-01-22
The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.
本发明涉及能与FXR结合并作为FXR调节剂的新型三环化合物,或其立体异构体、几何异构体、同分异构体、N-氧化物、水合物、溶质、代谢物、药学上可接受的盐或原药,以及该化合物用于治疗由FXR介导的疾病和/或病症的用途。本发明进一步提供了一种含有本文公开的化合物的药物组合物,以及一种治疗由FXR介导的疾病和/或病症的方法,该方法包括施用该化合物或药物组合物。